OA12267A - S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders. - Google Patents

S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders. Download PDF

Info

Publication number: OA12267A
Authority: OA; OAPI
Prior art keywords: disorder; condition; treated; use according; anxiety
Prior art date: 2000-06-02

Application number

OA1200200349A

Other languages

English (en)

Inventor

Chandra Aggarwal

Teresa Annette Smolarek

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-02

Filing date

2001-05-28

Publication date

2004-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-28 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2004-01-20 Publication of OA12267A publication Critical patent/OA12267A/en

Links

NHUDBVVEHOSVCD-UHFFFAOYSA-N 6-chloro-5-[2-[4-(2-methylsulfanylbenzenecarboximidoyl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one Chemical compound CSC1=CC=CC=C1C(=N)N1CCN(CCC=2C(=CC=3NC(=O)CC=3C=2)Cl)CC1 NHUDBVVEHOSVCD-UHFFFAOYSA-N 0.000 title claims description 12
208000022873 Ocular disease Diseases 0.000 title description 3
208000020016 psychiatric disease Diseases 0.000 title description 2
201000000980 schizophrenia Diseases 0.000 claims abstract description 12
241000124008 Mammalia Species 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 70
206010012289 Dementia Diseases 0.000 claims description 21
208000019901 Anxiety disease Diseases 0.000 claims description 20
208000028017 Psychotic disease Diseases 0.000 claims description 16
208000019022 Mood disease Diseases 0.000 claims description 14
230000036506 anxiety Effects 0.000 claims description 11
230000003542 behavioural effect Effects 0.000 claims description 11
206010026749 Mania Diseases 0.000 claims description 9
208000020706 Autistic disease Diseases 0.000 claims description 8
208000027691 Conduct disease Diseases 0.000 claims description 8
208000010412 Glaucoma Diseases 0.000 claims description 8
208000035475 disorder Diseases 0.000 claims description 8
208000000323 Tourette Syndrome Diseases 0.000 claims description 7
208000016620 Tourette disease Diseases 0.000 claims description 7
208000019906 panic disease Diseases 0.000 claims description 7
208000019899 phobic disease Diseases 0.000 claims description 7
208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
208000036626 Mental retardation Diseases 0.000 claims description 6
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
208000027465 Psychotic Affective disease Diseases 0.000 claims description 6
230000016571 aggressive behavior Effects 0.000 claims description 6
238000013019 agitation Methods 0.000 claims description 6
206010014557 Emotional poverty Diseases 0.000 claims description 5
208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
208000017442 Retinal disease Diseases 0.000 claims description 5
206010038923 Retinopathy Diseases 0.000 claims description 5
206010041243 Social avoidant behaviour Diseases 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
208000029364 generalized anxiety disease Diseases 0.000 claims description 5
230000004770 neurodegeneration Effects 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 3
208000026345 acute stress disease Diseases 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
230000036651 mood Effects 0.000 claims 2
206010034912 Phobia Diseases 0.000 claims 1
208000012981 Traumatic Stress disease Diseases 0.000 claims 1
230000002996 emotional effect Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 7
238000004519 manufacturing process Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
238000000034 method Methods 0.000 description 7
229960000607 ziprasidone Drugs 0.000 description 7
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 5
-1 salvés Substances 0.000 description 5
208000008811 Agoraphobia Diseases 0.000 description 4
208000020925 Bipolar disease Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
206010041250 Social phobia Diseases 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010012374 Depressed mood Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical class NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
206010065040 AIDS dementia complex Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010021030 Hypomania Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010052794 Panic disorder with agoraphobia Diseases 0.000 description 1
206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
208000011962 Substance-induced mood disease Diseases 0.000 description 1
231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000009985 drug-induced dyskinesia Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Chemical class 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000037870 generalized anxiety Diseases 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
229940083608 sodium hydroxide Drugs 0.000 description 1
235000011121 sodium hydroxide Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940032330 sulfuric acid Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
208000018726 traumatic encephalopathy Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200200349A 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders. OA12267A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20913600P	2000-06-02	2000-06-02
US21217200P	2000-06-16	2000-06-16

Publications (1)

Publication Number	Publication Date
OA12267A true OA12267A (en)	2004-01-20

Family

ID=26903852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200349A OA12267A (en)	2000-06-02	2001-05-28	S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders.

Country Status (44)

Country	Link
US (1)	US20060287336A1 (fr)
EP (3)	EP1286672B1 (fr)
JP (2)	JP2003534381A (fr)
KR (1)	KR20030007824A (fr)
CN (1)	CN1431901A (fr)
AP (2)	AP1831A (fr)
AR (1)	AR028937A1 (fr)
AT (3)	ATE343387T1 (fr)
AU (1)	AU2001258690A1 (fr)
BG (1)	BG107267A (fr)
BR (1)	BR0111271A (fr)
CA (1)	CA2410618A1 (fr)
CY (1)	CY1105992T1 (fr)
CZ (1)	CZ20023860A3 (fr)
DE (3)	DE60124791T2 (fr)
DK (1)	DK1468686T3 (fr)
DO (1)	DOP2001000181A (fr)
EA (1)	EA007068B1 (fr)
EC (1)	ECSP024369A (fr)
EE (1)	EE200200670A (fr)
ES (1)	ES2277170T3 (fr)
GE (1)	GEP20053512B (fr)
HN (1)	HN2001000119A (fr)
HR (1)	HRP20020953A2 (fr)
HU (1)	HUP0301747A2 (fr)
IL (2)	IL152782A0 (fr)
IS (1)	IS6619A (fr)
MA (1)	MA26908A1 (fr)
MX (1)	MXPA02011862A (fr)
NO (1)	NO325077B1 (fr)
NZ (1)	NZ551012A (fr)
OA (1)	OA12267A (fr)
PA (1)	PA8518301A1 (fr)
PE (1)	PE20011329A1 (fr)
PL (1)	PL365576A1 (fr)
PT (2)	PT1698338E (fr)
SI (1)	SI1468686T1 (fr)
SK (1)	SK16622002A3 (fr)
SV (1)	SV2002000473A (fr)
UA (1)	UA79425C2 (fr)
UY (1)	UY26742A1 (fr)
WO (1)	WO2001091756A2 (fr)
YU (1)	YU90702A (fr)
ZA (1)	ZA200209665B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7419493B2 (en)	2002-12-13	2008-09-02	Regents Of The University Of Minnesota	Scleral depressor
EP1628973A2 (fr)	2003-10-24	2006-03-01	Teva Pharmaceutical Industries Ltd.	Procedes de preparation de ziprasidone
ES2250001B1 (es) *	2004-09-29	2007-06-01	Medichem, S.A.	Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) *	2011-02-24	2012-09-10	Kyocera Corp	プログラム保護装置および通信装置
WO2014078568A1 (fr)	2012-11-14	2014-05-22	The Johns Hopkins University	Méthodes et compositions pour le traitement de la schizophrénie
US9981041B2 (en) *	2016-08-23	2018-05-29	Ira Jason Salzman	Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW491847B (en) *	1996-05-07	2002-06-21	Pfizer	Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
CA2252895C (fr) *	1996-05-07	2002-08-20	Pfizer Inc.	Trihydrate du sel mesylate de 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), sa preparation et son utilisation en tant qu'antagoniste du recepteur dopaminergique d2
ATE247963T1 (de) *	1998-05-26	2003-09-15	Pfizer Prod Inc	Medikament zur behandlung von glaukoma und ischämischer retinopathie
AU4062900A (en) *	1999-04-06	2000-10-23	Sepracor, Inc.	Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites

2001
- 2001-05-28 CA CA002410618A patent/CA2410618A1/fr not_active Abandoned
- 2001-05-28 AT AT01932011T patent/ATE343387T1/de not_active IP Right Cessation
- 2001-05-28 YU YU90702A patent/YU90702A/sh unknown
- 2001-05-28 AT AT04013380T patent/ATE345818T1/de not_active IP Right Cessation
- 2001-05-28 JP JP2001587771A patent/JP2003534381A/ja not_active Withdrawn
- 2001-05-28 ES ES04013380T patent/ES2277170T3/es not_active Expired - Lifetime
- 2001-05-28 IL IL15278201A patent/IL152782A0/xx active IP Right Grant
- 2001-05-28 EP EP01932011A patent/EP1286672B1/fr not_active Expired - Lifetime
- 2001-05-28 BR BR0111271-6A patent/BR0111271A/pt not_active Application Discontinuation
- 2001-05-28 DE DE60124791T patent/DE60124791T2/de not_active Expired - Fee Related
- 2001-05-28 EP EP04013380A patent/EP1468686B1/fr not_active Expired - Lifetime
- 2001-05-28 SI SI200130681T patent/SI1468686T1/sl unknown
- 2001-05-28 CZ CZ20023860A patent/CZ20023860A3/cs unknown
- 2001-05-28 PL PL01365576A patent/PL365576A1/xx unknown
- 2001-05-28 HR HR20020953A patent/HRP20020953A2/hr not_active Application Discontinuation
- 2001-05-28 WO PCT/IB2001/000933 patent/WO2001091756A2/fr not_active Ceased
- 2001-05-28 NZ NZ551012A patent/NZ551012A/en unknown
- 2001-05-28 AT AT06116051T patent/ATE391507T1/de not_active IP Right Cessation
- 2001-05-28 EA EA200201168A patent/EA007068B1/ru not_active IP Right Cessation
- 2001-05-28 SK SK1662-2002A patent/SK16622002A3/sk not_active Application Discontinuation
- 2001-05-28 GE GE4972A patent/GEP20053512B/en unknown
- 2001-05-28 KR KR1020027016364A patent/KR20030007824A/ko not_active Ceased
- 2001-05-28 DK DK04013380T patent/DK1468686T3/da active
- 2001-05-28 PT PT06116051T patent/PT1698338E/pt unknown
- 2001-05-28 AU AU2001258690A patent/AU2001258690A1/en not_active Abandoned
- 2001-05-28 DE DE60124093T patent/DE60124093D1/de not_active Expired - Lifetime
- 2001-05-28 MX MXPA02011862A patent/MXPA02011862A/es active IP Right Grant
- 2001-05-28 OA OA1200200349A patent/OA12267A/en unknown
- 2001-05-28 PT PT04013380T patent/PT1468686E/pt unknown
- 2001-05-28 CN CN01810620A patent/CN1431901A/zh active Pending
- 2001-05-28 HU HU0301747A patent/HUP0301747A2/hu unknown
- 2001-05-28 DE DE60133596T patent/DE60133596D1/de not_active Expired - Lifetime
- 2001-05-28 UA UA2002119557A patent/UA79425C2/uk unknown
- 2001-05-28 EE EEP200200670A patent/EE200200670A/xx unknown
- 2001-05-28 EP EP06116051A patent/EP1698338B1/fr not_active Expired - Lifetime
- 2001-05-31 HN HN2001000119A patent/HN2001000119A/es unknown
- 2001-05-31 DO DO2001000181A patent/DOP2001000181A/es unknown
- 2001-05-31 AP APAP/P/2001/002180A patent/AP1831A/en active
- 2001-05-31 AP AP2005003272A patent/AP1747A/xx active
- 2001-05-31 PE PE2001000504A patent/PE20011329A1/es not_active Application Discontinuation
- 2001-05-31 UY UY26742A patent/UY26742A1/es not_active Application Discontinuation
- 2001-06-01 AR ARP010102641A patent/AR028937A1/es unknown
- 2001-06-01 SV SV2001000473A patent/SV2002000473A/es not_active Application Discontinuation
- 2001-06-01 PA PA20018518301A patent/PA8518301A1/es unknown
- 2001-06-04 US US09/873,973 patent/US20060287336A1/en not_active Abandoned
2002
- 2002-11-11 IL IL152782A patent/IL152782A/en not_active IP Right Cessation
- 2002-11-12 BG BG107267A patent/BG107267A/bg unknown
- 2002-11-14 IS IS6619A patent/IS6619A/is unknown
- 2002-11-28 ZA ZA200209665A patent/ZA200209665B/en unknown
- 2002-11-29 MA MA26927A patent/MA26908A1/fr unknown
- 2002-11-29 NO NO20025760A patent/NO325077B1/no unknown
- 2002-11-29 EC EC2002004369A patent/ECSP024369A/es unknown
2007
- 2007-02-08 CY CY20071100161T patent/CY1105992T1/el unknown
- 2007-11-14 JP JP2007296039A patent/JP2008056700A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2001258690A1 (en)	2001-12-11
EP1286672A2 (fr)	2003-03-05
ECSP024369A (es)	2003-02-06
AP1747A (en)	2007-05-31
EA200201168A1 (ru)	2003-06-26
SI1468686T1 (sl)	2007-04-30
DE60124791T2 (de)	2007-09-13
WO2001091756A2 (fr)	2001-12-06
JP2008056700A (ja)	2008-03-13
PT1698338E (pt)	2008-06-03
UA79425C2 (en)	2007-06-25
MA26908A1 (fr)	2004-12-20
DE60124093D1 (de)	2006-12-07
ATE343387T1 (de)	2006-11-15
BR0111271A (pt)	2003-06-10
DE60124791D1 (de)	2007-01-04
EP1468686A2 (fr)	2004-10-20
DOP2001000181A (es)	2002-04-15
HN2001000119A (es)	2001-09-11
GEP20053512B (en)	2005-05-10
NO20025760D0 (no)	2002-11-29
IL152782A (en)	2007-10-31
DK1468686T3 (da)	2007-03-12
US20060287336A1 (en)	2006-12-21
ATE391507T1 (de)	2008-04-15
CA2410618A1 (fr)	2001-12-06
UY26742A1 (es)	2001-12-28
CN1431901A (zh)	2003-07-23
NO325077B1 (no)	2008-01-28
WO2001091756A3 (fr)	2002-09-26
DE60133596D1 (de)	2008-05-21
CY1105992T1 (el)	2011-04-06
EP1698338B1 (fr)	2008-04-09
JP2003534381A (ja)	2003-11-18
EP1698338A3 (fr)	2006-09-20
SK16622002A3 (sk)	2004-07-07
MXPA02011862A (es)	2003-04-10
HUP0301747A2 (hu)	2003-09-29
EA007068B1 (ru)	2006-06-30
AP2005003272A0 (en)	2005-03-31
PT1468686E (pt)	2007-01-31
PE20011329A1 (es)	2002-01-15
PA8518301A1 (es)	2002-09-17
SV2002000473A (es)	2002-10-24
EP1468686B1 (fr)	2006-11-22
EE200200670A (et)	2004-08-16
EP1698338A2 (fr)	2006-09-06
IL152782A0 (en)	2003-06-24
AP1831A (en)	2008-02-26
ATE345818T1 (de)	2006-12-15
AR028937A1 (es)	2003-05-28
ES2277170T3 (es)	2007-07-01
BG107267A (bg)	2003-06-30
YU90702A (sh)	2005-11-28
EP1468686A3 (fr)	2004-12-01
NO20025760L (no)	2003-01-15
PL365576A1 (en)	2005-01-10
EP1286672B1 (fr)	2006-10-25
ZA200209665B (en)	2003-11-28
HRP20020953A2 (en)	2005-02-28
NZ551012A (en)	2008-04-30
CZ20023860A3 (cs)	2004-01-14
IS6619A (is)	2002-11-14
KR20030007824A (ko)	2003-01-23

Publication	Publication Date	Title
DE60017898T2 (de)	2006-01-12	Neuartige heterocyclische carboxamidderivate
JPH06504548A (ja)	1994-05-26	光学的に活性な５Ｈ−ピロロ［３，４−ｂ］ピラジン誘導体、それの製造およびそれを含有している薬学的組成物
JP2951313B2 (ja)	1999-09-20	フルオロ置換アダマンタン誘導体
JPH10310581A (ja)	1998-11-24	複素環式エステル、アミド、チオエステルおよびケトンのｎ−オキシド
JP2008056700A (ja)	2008-03-13	精神障害及び眼障害の治療用ｓ−メチル−ジヒドロ−ジプラシドン
EP0495709A1 (fr)	1992-07-22	Nouveaux composés de structure aryltriazinique leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN119564657A (zh)	2025-03-07	衣康酸酯及其衍生物/类似物诱导毛发生长的用途
EP2493305B1 (fr)	2015-03-25	Composés 2-aminoindoles et méthodes de traitement de la malaria
EP0136143B1 (fr)	1987-11-04	Spirosuccinimides et leur utilisation dans le traitement des complications du diabète
JPH0573754B2 (fr)	1993-10-15
JP2006502168A5 (fr)	2006-08-24
AU2007202939A1 (en)	2007-07-19	S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
KR20180020119A (ko)	2018-02-27	새로운 5형포스포디에스테라아제 억제제 및 그 용도
JPH03218361A (ja)	1991-09-25	９―アシルアミノテトラヒドロアクリジン誘導体
CH629194A5 (fr)	1982-04-15	Amino aryl triazines-1,2,4 utilisables dans le traitement d'algies diverses.
HK1053615A (en)	2003-10-31	S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
OA21205A (en)	2024-02-29	Tetrahydroisoquinoline derivatives for the treatment of red blood disorders and inflammatory diseases.
HK1175072B (en)	2016-01-15	2-aminoindole compounds and methods for the treatment of malaria
BE882223A (fr)	1980-09-15	Derives d'amine-3 (1h, 3) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
JPWO1999044639A1 (ja)	2002-10-15	脳梗塞治療剤